Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast Foam 0.3% in Hidradenitis Suppurativa
NCT07263230Phase 2Recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of roflumilast vehicle cream in hidradenitis suppurativa (HS), sponsored by Beth Israel Deaconess Medical Center. Started Sep 2026; status: recruiting.
02
Drugs
roflumilast vehicle cream
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07263230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263230.